Has the Canadian Biotech Industry valuation changed over the past few years?

Investors are more pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 12.7x which is lower than its 3-year average PE of 98.4x.

How does Canadian Biotech compare with similar industries?

There is insufficient data on the sub-industries of this industry.

Canadian (TSX) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE
Sat, 28 May 2022	CA$3.1b	CA$180.1m	-CA$456,438,515.00	12.7x
Mon, 25 Apr 2022	CA$3.4b	CA$175.8m	-CA$489,690,985.00	14x
Wed, 23 Mar 2022	CA$3.3b	CA$171.0m	-CA$479,666,992.00	13.8x
Fri, 18 Feb 2022	CA$3.5b	CA$167.6m	-CA$454,286,480.00	17.8x
Sun, 16 Jan 2022	CA$3.4b	CA$166.4m	-CA$429,998,987.00	19.6x
Tue, 14 Dec 2021	CA$5.9b	CA$172.9m	-CA$495,408,256.00	5.2x
Thu, 11 Nov 2021	CA$6.0b	CA$171.0m	-CA$424,877,138.00	7.4x
Sat, 09 Oct 2021	CA$7.9b	CA$240.5m	-CA$608,032,848.00	8.1x
Mon, 06 Sep 2021	CA$8.0b	CA$222.8m	-CA$562,923,623.08	7.2x
Wed, 04 Aug 2021	CA$3.4b	CA$161.7m	-CA$474,887,008.08	26.2x
Sat, 08 May 2021	CA$4.4b	CA$154.4m	-CA$492,315,138.31	16x
Tue, 09 Feb 2021	CA$3.8b	CA$64.4m	-CA$334,394,309.22	22.6x
Mon, 02 Nov 2020	CA$3.7b	CA$144.2m	-CA$423,056,348.42	6.1x
Thu, 06 Aug 2020	CA$3.2b	CA$155.6m	-CA$395,109,095.79	6.9x
Sun, 10 May 2020	CA$3.1b	CA$155.4m	-CA$339,174,105.67	42.4x
Sat, 01 Feb 2020	CA$2.8b	CA$161.7m	-CA$234,737,086.87	n/a
Tue, 05 Nov 2019	CA$1.8b	CA$164.5m	-CA$244,388,675.87	744.4x
Fri, 09 Aug 2019	CA$1.9b	CA$163.5m	-CA$234,009,186.88	n/a


CA Market	1.68%
Healthcare	0.16%
Biotech	-4.11%
Biotech	-4.11%

Company	Last Price	7D	1Y	Valuation
TH Theratechnologies	CA$3.14	7.2% +CA$20.0m	-25.6%	PS3.2x
MGRO MustGrow Biologics	CA$3.05	7.0% +CA$9.8m	60.5%	PS10517.2x
MBX Microbix Biosystems	CA$0.57	9.6% +CA$6.9m	-3.4%	PS20x
ONC Oncolytics Biotech	CA$1.45	7.4% +CA$5.8m	-60.7%	PB2.4x
COV Covalon Technologies	CA$2.09	7.2% +CA$3.7m	44.1%	PS156.9x

May 10

U.S. Food and Drug Administration Grants Resverlogix Corp. Request for Type C Meeting to Review Clinical Trial Protocol for Phase 3 Study

Resverlogix Corp. announced that the U.S. Food and Drug Administration has granted the Company's request for a Type C meeting to review the clinical trial protocol for its Phase 3 study of apabetalone in high-risk COVID-19 outpatients. The meeting is scheduled for early August. In response to the transformation of the COVID-19 pandemic, advancement to the Phase 3 trial will target outpatients with multiple risk factors for serious outcomes, focusing where apabetalone has the potential to impact patient outcomes. Company will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program. By targeting outpatients with multiple risk factors for serious outcomes, Company aims to lessen the strain on healthcare systems keeping COVID-19 patients out of hospitals by reducing disease severity in the short and long-term. CORAL Study Design. The Phase 3, multicenter, randomized clinical trial, entitled: A Double-Blind Placebo Controlled Study to Assess the Efficacy and Safety of Oral Company in Elderly Subjects with Covid-19 Infection and High Risk for Severe Illness and to Explore the Potential to Limit Long-Term Symptoms, will evaluate the safety and efficacy of Company in preventing serious health outcomes in high-risk COVID-19 patients. Study site selection is currently underway, with sites expected in the United States, Canada, and the Middle East. High-risk COVID-19 Patients. A recently published, large-scale analysis of electronic health records, found that individuals who have contracted COVID-19 are at significantly greater long-term risk for a broad range of negative cardiovascular outcomes, including acute coronary disease, heart attack, stroke, and heart failure, compared to those who had never had the disease . The study found elevated risks persisted long after the initial infection, even in people who were not hospitalized for COVID-19, and were most pronounced among high-risk patients including those with a history of cardiovascular disease, those with pre-existing comorbidities and those over the age of 65.

Canadian (TSX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

COV

Covalon Technologies Ltd. to Report Q2, 2022 Results on May 30, 2022

ACOG

Alpha Cognition Inc., Annual General Meeting, Jul 19, 2022

TH

Theratechnologies (TSE:TH) Is Making Moderate Use Of Debt

IMV

Consensus revenue estimates increase by 11%

HBP

Helix BioPharma Corp. Appoints Namrata Malhotra as Corporate Secretary

MBX

Microbix Biosystems' (TSE:MBX) Solid Profits Have Weak Fundamentals

EDT

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

BLU

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ONC

Consensus forecasts updated

MGRO

MustGrow Biologics Corp., Annual General Meeting, Jun 29, 2022

RVX

U.S. Food and Drug Administration Grants Resverlogix Corp. Request for Type C Meeting to Review Clinical Trial Protocol for Phase 3 Study

BCT

We're Not Very Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Rate

APS

Aptose Receives Fast Track Designation for Hm43239 in Relapsed/Refractory Aml Patients and Flt3 Mutation

SBM

Less than half of directors are independent

EPRX

Price target decreased to CA$6.50

DRUG

High number of new and inexperienced directors